Cytori Therapeutics expanded its international distribution network for the Celution™ System in reconstructive surgery. The four additional distributors will cover Belgium, Greece, Israel, Luxembourg, The Netherlands, and Taiwan. These groups will oversee product sales and provide physician education and training in their respective territories.
"By adding these important distribution partners, Cytori continues to execute its international commercialization strategy," said Bruce Reuter, senior vice president of international sales, marketing and distribution.
"We look forward to their support of our targeted launch of the Celution™ System early next year in Europe and select countries in Asia-Pacific for use in reconstructive surgery. This sets the stage for our broader international launch in 2009 following the completion of our breast reconstruction reimbursement study."
Cytori selected its distribution partners based upon experience in the reconstructive surgery market, track record of introducing new technologies, proven sales performance in their respective regions, and specialized regulatory and training expertise.
The new distributors are BlooMEDical Benelux NV, which will serve Belgium, Luxembourg, and The Netherlands; Arthrosis S.A., which will serve Greece; AMI Technologies Ltd., which will serve Israel, and North West Co. Ltd., which will serve Taiwan.
Cytori's Celution™ System is a medical device that removes a patient's own regenerative cells from their adipose (fat) tissue in about an hour. The cells can then be delivered to the same patient at the bedside in the same surgical procedure.